Download or read book Clinic and Functional Analysis of P73R1 Mutations in Prostate Cancer written by and published by . This book was released on 2006 with total page 40 pages. Available in PDF, EPUB and Kindle. Book excerpt: The DNA damage-signaling pathway has been implicated in the development of prostate cancer since germline mutations in several genes (BRCA1, BRCA2, and CHEK2) whose products are involved in this pathway have been associated with increased risk for this cancer. We previously isolated a novel p73 up-regulated gene (p73R1) and identified p73R1 mutations in prostate cancer. In this report, we screened 856 unselected prostate cancer specimens and detected a frequency of 2.6% (221856) truncation mutations in prostate cancers in contrast to 0.6% (21327) in 327 population-based controls (Fishers exact test, P = 0.036), with an odds ratio of 4.3 (95% confidence interval 1.2 - 21.2). In addition, we also demonstrated that mutant p73R1 was unable to induce apoptosis and suppress cell growth in HeLa and Cos7 cells. The loss of function mutation in p73R1 is due to the inability of the mutant to induce cytochrome c release from mitochondria. These results suggest that loss of function mutations in p73R1 predispose men to prostate cancer and further support the concept that the genetic defects in the DNA damage-response genes play an important role in the development of prostate cancer.

Download or read book Clinical and Functional Analyses of P73R1 Mutations in Prostate Cancer written by and published by . This book was released on 2005 with total page 25 pages. Available in PDF, EPUB and Kindle. Book excerpt: The DNA damage-signaling pathway has been implicated in the development of prostate cancer. Germline mutations in several genes (BRCA1, BRCA2, and CHEK2) whose products are involved in this pathway have been associated with increased risk for this disease. To identify additional genes in this pathway that might confer susceptibility to prostate cancer, we isolated a p73 up-regulated gene (p73R1) and screened this gene for mutations in prostate cancer. Two germline truncating mutations were identified. Genotyping of 403 men with sporadic prostate cancer for the two mutations showed a frequency of 3.2% (13/403) in contrast to 0.6% (2/327) in 327 population-based controls (Fisher's exact test, P=0.016), with an odds ratio of 5.4 (95% confidence interval 1.2-24.2). Analyses of 994 affected men from 444 familial prostate cancer families showed a relatively lower frequency of 1.6% but no mutations were found in 100 unaffected men from these families, indicating a similar trend observed for other comparisons. Overall, our data suggest that germline p73R1 truncating mutations may predispose men to prostate cancer and further supports the concept that the mutant alleles in the DNA damage-response genes play an important role in the development of sporadic prostate cancer.